Key Points
- Insider sale: Stoke Therapeutics General Counsel Jonathan Allan sold 627 shares for approximately $16,509 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 2.95% to 20,598 shares.
- Stock and financial performance: STOK opened at $25.62, below its 50-day and 200-day moving averages. The company recently reported a quarterly loss of $0.93 per share, missing expectations, despite revenue of $9.32 million exceeding estimates.
- Analyst outlook: Wall Street maintains a “Moderate Buy” consensus, with 10 Buy ratings and one Sell rating and an average price target of $44.25 versus the reported share price.
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 627 shares of the business's stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $26.33, for a total value of $16,508.91. Following the completion of the sale, the general counsel directly owned 20,598 shares of the company's stock, valued at $542,345.34. This represents a 2.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jonathan Allan also recently made the following trade(s):
- On Tuesday, August 18th, Jonathan Allan sold 2,861 shares of Stoke Therapeutics stock. The shares were sold at an average price of $32.03, for a total value of $91,637.83.
Stoke Therapeutics Stock Performance
Shares of NASDAQ STOK opened at $25.62 on Friday. The business's 50-day simple moving average is $29.91 and its 200-day simple moving average is $31.17. Stoke Therapeutics, Inc. has a 52 week low of $20.32 and a 52 week high of $40.22. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of -7.67 and a beta of 1.26.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The company had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%. As a group, equities research analysts forecast that Stoke Therapeutics, Inc. will post -3.52 earnings per share for the current year.
Wall Street Analyst Weigh In
Several brokerages recently commented on STOK. Guggenheim reiterated a "buy" rating and issued a $60.00 target price on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Wedbush lifted their price objective on Stoke Therapeutics from $38.00 to $40.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 4th. Weiss Ratings reissued a "sell (d)" rating on shares of Stoke Therapeutics in a research report on Friday, August 7th. Canaccord Genuity Group decreased their target price on Stoke Therapeutics from $60.00 to $58.00 and set a "buy" rating for the company in a research note on Tuesday, August 4th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Stoke Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $44.25.
Read Our Latest Research Report on Stoke Therapeutics
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in STOK. Versant Capital Management Inc lifted its stake in shares of Stoke Therapeutics by 22.6% in the second quarter. Versant Capital Management Inc now owns 1,951 shares of the company's stock valued at $64,000 after buying an additional 359 shares during the period. First Trust Advisors LP increased its stake in Stoke Therapeutics by 0.5% during the first quarter. First Trust Advisors LP now owns 163,459 shares of the company's stock valued at $5,322,000 after acquiring an additional 780 shares during the period. Harbour Investments Inc. increased its stake in Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company's stock valued at $38,000 after acquiring an additional 898 shares during the period. Quantbot Technologies LP bought a new position in Stoke Therapeutics during the second quarter valued at about $34,000. Finally, KBC Group NV acquired a new position in Stoke Therapeutics in the 1st quarter valued at approximately $36,000.
Stoke Therapeutics Company Profile
(
Get Free Report)
Stoke Therapeutics, Inc is a biotechnology company developing genetic medicines for severe diseases caused by inadequate protein expression. The company's approach, known as TANGO (Targeted Augmentation of Nuclear Gene Output), uses antisense oligonucleotides to selectively modulate pre-messenger RNA splicing and increase production of functional proteins from disease-associated genes.
Stoke's lead program is zorevunersen (STK-001), an investigational antisense oligonucleotide designed to increase functional NaV1.1 protein expression in people with Dravet syndrome, a severe genetic epilepsy caused primarily by mutations in the SCN1A gene.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
